SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

NASDAQ:SNSE • US81728A2078

30.22 USD
-4.01 (-11.71%)
At close: Feb 26, 2026
30.6 USD
+0.38 (+1.26%)
After Hours: 2/26/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, SNSE scores 2 out of 10 in our fundamental rating. SNSE was compared to 521 industry peers in the Biotechnology industry. SNSE has a great financial health rating, but its profitability evaluates not so good. SNSE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SNSE has reported negative net income.
  • SNSE had a negative operating cash flow in the past year.
  • In the past 5 years SNSE always reported negative net income.
  • In the past 5 years SNSE always reported negative operating cash flow.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • SNSE has a Return On Assets of -87.50%. This is in the lower half of the industry: SNSE underperforms 71.40% of its industry peers.
  • SNSE has a Return On Equity (-104.92%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -87.5%
ROE -104.92%
ROIC N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

  • SNSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, SNSE has more shares outstanding
  • The number of shares outstanding for SNSE has been reduced compared to 5 years ago.
  • SNSE has a better debt/assets ratio than last year.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • SNSE has an Altman-Z score of -11.16. This is a bad value and indicates that SNSE is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of SNSE (-11.16) is worse than 74.47% of its industry peers.
  • SNSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.16
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.81 indicates that SNSE has no problem at all paying its short term obligations.
  • The Current ratio of SNSE (5.81) is better than 61.04% of its industry peers.
  • A Quick Ratio of 5.81 indicates that SNSE has no problem at all paying its short term obligations.
  • The Quick ratio of SNSE (5.81) is better than 62.19% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • SNSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.62%, which is quite good.
EPS 1Y (TTM)19.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SNSE will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.36% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.78%
EPS Next 2Y16.64%
EPS Next 3Y13.75%
EPS Next 5Y8.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SNSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SNSE's earnings are expected to grow with 13.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.64%
EPS Next 3Y13.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SNSE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (2/26/2026, 8:00:02 PM)

After market: 30.6 +0.38 (+1.26%)

30.22

-4.01 (-11.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-26
Inst Owners4.04%
Inst Owner Change-1.55%
Ins Owners2.23%
Ins Owner Change-0.27%
Market Cap38.08M
Revenue(TTM)N/A
Net Income(TTM)-24.14M
Analysts43.33
Price Target33.15 (9.7%)
Short Float %3.03%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.6%
Min EPS beat(2)13.65%
Max EPS beat(2)31.55%
EPS beat(4)2
Avg EPS beat(4)4.21%
Min EPS beat(4)-18.53%
Max EPS beat(4)31.55%
EPS beat(8)5
Avg EPS beat(8)2.63%
EPS beat(12)9
Avg EPS beat(12)4.93%
EPS beat(16)11
Avg EPS beat(16)3.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-19.13
EYN/A
EPS(NY)-15.35
Fwd EYN/A
FCF(TTM)-17.78
FCFYN/A
OCF(TTM)-17.76
OCFYN/A
SpS0
BVpS18.26
TBVpS18.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.5%
ROE -104.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -11.16
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.02%
Cap/Depr(5y)183.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.59%
EPS Next Y22.78%
EPS Next 2Y16.64%
EPS Next 3Y13.75%
EPS Next 5Y8.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.94%
EBIT Next 3Y0.09%
EBIT Next 5YN/A
FCF growth 1Y37.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.85%
OCF growth 3YN/A
OCF growth 5YN/A

SENSEI BIOTHERAPEUTICS INC / SNSE FAQ

Can you provide the ChartMill fundamental rating for SENSEI BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SNSE.


What is the valuation status of SENSEI BIOTHERAPEUTICS INC (SNSE) stock?

ChartMill assigns a valuation rating of 0 / 10 to SENSEI BIOTHERAPEUTICS INC (SNSE). This can be considered as Overvalued.


How profitable is SENSEI BIOTHERAPEUTICS INC (SNSE) stock?

SENSEI BIOTHERAPEUTICS INC (SNSE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SENSEI BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of SENSEI BIOTHERAPEUTICS INC (SNSE) is expected to grow by 22.78% in the next year.